- Radiologically isolated syndrome is diagnosed in people who do not have multiple sclerosis (MS) symptoms but who have lesions (abnormalities) in the brain and/or spinal cord, similar to those seen in MS, but with no other symptoms.
- The phase 3 TERIS study enrolled individuals with RIS from Europe and Turkey and analyzed the efficacy of the drug teriflunomide (Aubagio®) in delaying the first symptoms of MS.
- Treatment with teriflunomide resulted in a 63% risk reduction relative to placebo in preventing the first symptoms of MS in individuals with RIS.
- The findings of the TERIS study support the idea that it may be beneficial to treat RIS with medication that can change the course of the disease before any symptoms of MS appear.
An estimated
Some people have lesions (abnormalities) in the brain and/or spinal cord, similar to those seen in MS, but no other symptoms. This is a rare condition known as
A
Researchers have hypothesized that treating RIS at an early stage could prevent the occurrence of the first clinical event and reduce the risk of new lesion development in the brain or spinal cord. This could decrease the risk of permanent neurological damage.
The ARISE study, published in 2022, investigated the use of dimethyl fumarate (Tecfidera; Biogen) in patients with RIS. The study found that treatment with dimethyl fumarate significantly reduced the risk of the first clinical demyelinating event (nerve damage) in people with RIS.
Now, the results of a sister study to ARISE – the TERIS study – have been released. This phase 3 study assessed the efficacy of the drug
Read the full article here